SC Pharmaceuticals Inc (SCPH)

$3.28 -0.14 (-4.09%)
Market Cap 171.14M
Revenue (ttm) 13.59M
Net Income (ttm) -54.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -403.31%
Debt to Equity Ratio 1.66
Volume 207,100
Avg Vol 488,618
Day's Range N/A - N/A
Shares Out 50.04M
Stochastic %K 31%
Beta 0.11
Analysts Strong Sell
Price Target $17.50

Latest News on SCPH

scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

Jan 10, 2025, 8:00 AM EST - 7 days ago

scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

scPharmaceuticals Inc. (SCPH) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 7:05 PM EST - 2 months ago

scPharmaceuticals Inc. (SCPH) Q3 2024 Earnings Call Transcript

scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 13, 2024, 4:01 PM EST - 2 months ago

scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update

scPharmaceuticals to Announce Third Quarter 2024 Financial Results on Wednesday, November 13, 2024

Nov 6, 2024, 4:01 PM EST - 2 months ago

scPharmaceuticals to Announce Third Quarter 2024 Financial Results on Wednesday, November 13, 2024

scPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October 22, 2024

Oct 15, 2024, 8:30 AM EDT - 3 months ago

scPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October 22, 2024

scPharmaceuticals Inc. (SCPH) Q2 2024 Earnings Call Transcript

Aug 15, 2024, 5:10 AM EDT - 5 months ago

scPharmaceuticals Inc. (SCPH) Q2 2024 Earnings Call Transcript

scPharmaceuticals Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 14, 2024, 4:01 PM EDT - 5 months ago

scPharmaceuticals Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

scPharmaceuticals Announces Pricing of $50.0 Million Public Offering

Aug 12, 2024, 9:48 AM EDT - 5 months ago

scPharmaceuticals Announces Pricing of $50.0 Million Public Offering

scPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $125 Million with Perceptive Advisors

Aug 12, 2024, 6:05 AM EDT - 5 months ago

scPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $125 Million with Perceptive Advisors

scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart Failure

Aug 12, 2024, 6:04 AM EDT - 5 months ago

scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart Failure

scPharmaceuticals Announces Positive Topline Study Results for SCP-111 (Furosemide 80 mg/1 mL) Autoinjector

Aug 12, 2024, 6:02 AM EDT - 5 months ago

scPharmaceuticals Announces Positive Topline Study Results for SCP-111 (Furosemide 80 mg/1 mL) Autoinjector

scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Aug 12, 2024, 6:00 AM EDT - 5 months ago

scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

scPharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 29, 2024, 4:01 PM EDT - 8 months ago

scPharmaceuticals to Present at the Jefferies Global Healthcare Conference

scPharmaceuticals Inc. (SCPH) Q1 2024 Earnings Call Transcript

May 14, 2024, 7:02 PM EDT - 8 months ago

scPharmaceuticals Inc. (SCPH) Q1 2024 Earnings Call Transcript

scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

May 14, 2024, 4:01 PM EDT - 8 months ago

scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

scPharmaceuticals to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 13, 2024, 4:05 PM EDT - 8 months ago

scPharmaceuticals to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

scPharmaceuticals to Announce First Quarter 2024 Financial Results on Tuesday, May 14, 2024

May 7, 2024, 4:05 PM EDT - 9 months ago

scPharmaceuticals to Announce First Quarter 2024 Financial Results on Tuesday, May 14, 2024

scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection

Apr 24, 2024, 8:00 AM EDT - 9 months ago

scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection

scPharmaceuticals Inc (SCPH) Q4 2023 Earnings Call Transcript

Mar 13, 2024, 7:32 PM EDT - 11 months ago

scPharmaceuticals Inc (SCPH) Q4 2023 Earnings Call Transcript

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Mar 13, 2024, 4:01 PM EDT - 11 months ago

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024

Mar 6, 2024, 4:01 PM EST - 11 months ago

scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024

scPharmaceuticals to Participate in Two Upcoming Investor Conferences

Feb 28, 2024, 4:01 PM EST - 11 months ago

scPharmaceuticals to Participate in Two Upcoming Investor Conferences

scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue

Jan 4, 2024, 4:05 PM EST - 1 year ago

scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue

scPharmaceuticals Q3 Earnings: Cruising Toward Success

Nov 12, 2023, 2:57 AM EST - 1 year ago

scPharmaceuticals Q3 Earnings: Cruising Toward Success

scPharmaceuticals Inc (SCPH) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 9:58 PM EST - 1 year ago

scPharmaceuticals Inc (SCPH) Q3 2023 Earnings Call Transcript

scPharmaceuticals Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 8, 2023, 4:01 PM EST - 1 year ago

scPharmaceuticals Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update

scPharmaceuticals to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

Nov 1, 2023, 4:05 PM EDT - 1 year ago

scPharmaceuticals to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 5, 2023, 8:00 AM EDT - 1 year ago

scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

scPharmaceuticals: Furoscix, Charting A Bright Future With FDA's Nod For CKD

Sep 27, 2023, 12:40 AM EDT - 1 year ago

scPharmaceuticals: Furoscix, Charting A Bright Future With FDA's Nod For CKD

scPharmaceuticals Announces Positive Feedback from Two FDA Meetings on Key Long-Term Growth Initiatives

Sep 19, 2023, 8:00 AM EDT - 1 year ago

scPharmaceuticals Announces Positive Feedback from Two FDA Meetings on Key Long-Term Growth Initiatives

Sizing Up scPharmaceuticals

Sep 13, 2023, 2:13 PM EDT - 1 year ago

Sizing Up scPharmaceuticals

scPharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 5, 2023, 8:00 AM EDT - 1 year ago

scPharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

scPharmaceuticals Inc. (SCPH) Q2 2023 Earnings Call Transcript

Aug 10, 2023, 10:38 PM EDT - 1 year ago

scPharmaceuticals Inc. (SCPH) Q2 2023 Earnings Call Transcript

scPharmaceuticals Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 10, 2023, 4:01 PM EDT - 1 year ago

scPharmaceuticals Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

scPharmaceuticals to Announce Second Quarter 2023 Financial Results on Thursday, August 10, 2023

Aug 3, 2023, 8:00 AM EDT - 1 year ago

scPharmaceuticals to Announce Second Quarter 2023 Financial Results on Thursday, August 10, 2023

scPharmaceuticals Announces Positive Type C Meeting Feedback from FDA on Potential Heart Failure Class IV Indication Expansion

Aug 1, 2023, 8:00 AM EDT - 1 year ago

scPharmaceuticals Announces Positive Type C Meeting Feedback from FDA on Potential Heart Failure Class IV Indication Expansion

scPharmaceuticals: Oversold Territory, Drug Launch Still Looks Robust

Jun 29, 2023, 11:05 PM EDT - 1 year ago

scPharmaceuticals: Oversold Territory, Drug Launch Still Looks Robust

scPharmaceuticals Inc. Announces Addition to Russell 2000® and Russell 3000® Indexes

Jun 23, 2023, 8:00 AM EDT - 1 year ago

scPharmaceuticals Inc. Announces Addition to Russell 2000® and Russell 3000® Indexes

scPharmaceuticals to Present at the Jefferies Healthcare Conference

May 31, 2023, 8:00 AM EDT - 1 year ago

scPharmaceuticals to Present at the Jefferies Healthcare Conference

scPharmaceuticals: Furoscix Firing On All Cylinders In Q1, Bullish Than Ever

May 20, 2023, 12:15 AM EDT - 1 year ago

scPharmaceuticals: Furoscix Firing On All Cylinders In Q1, Bullish Than Ever

scPharmaceuticals Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

May 10, 2023, 4:01 PM EDT - 1 year ago

scPharmaceuticals Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

scPharmaceuticals to Announce First Quarter 2023 Financial Results on Wednesday, May 10, 2023

May 2, 2023, 8:00 AM EDT - 1 year ago

scPharmaceuticals to Announce First Quarter 2023 Financial Results on Wednesday, May 10, 2023

scPharmaceuticals Inc. (SCPH) Q4 2022 Earnings Call Transcript

Mar 22, 2023, 8:11 PM EDT - 1 year ago

scPharmaceuticals Inc. (SCPH) Q4 2022 Earnings Call Transcript

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update

Mar 22, 2023, 4:05 PM EDT - 1 year ago

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update

scPharmaceuticals to Announce Fourth Quarter and Full-Year 2022 Financial Results on Wednesday, March 22

Mar 15, 2023, 8:00 AM EDT - 2 years ago

scPharmaceuticals to Announce Fourth Quarter and Full-Year 2022 Financial Results on Wednesday, March 22

scPharmaceuticals to Participate in the Cowen 43rd Annual Health Care Conference

Feb 23, 2023, 8:00 AM EST - 2 years ago

scPharmaceuticals to Participate in the Cowen 43rd Annual Health Care Conference

scPharmaceuticals Announces Launch and Commercial Availability of FUROSCIX® (furosemide injection)

Feb 21, 2023, 8:00 AM EST - 2 years ago

scPharmaceuticals Announces Launch and Commercial Availability of FUROSCIX® (furosemide injection)

scPharmaceuticals to Participate in the SVB Securities Global Biopharma Conference

Jan 31, 2023, 8:00 AM EST - 2 years ago

scPharmaceuticals to Participate in the SVB Securities Global Biopharma Conference

scPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial Update

Jan 30, 2023, 8:00 AM EST - 2 years ago

scPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial Update

scPharmaceuticals: Undervalued, De-Risked Cardiology Commercial Biotech, Initiating With A Buy

Jan 24, 2023, 8:15 AM EST - 2 years ago

scPharmaceuticals: Undervalued, De-Risked Cardiology Commercial Biotech, Initiating With A Buy